Question 1

What is Tibsovo?

Accepted Answer

Tibsovo works by blocking the activity of a mutated enzyme called isocitrate dehydrogenase-1 (IDH1). In certain cancers, this mutation leads to the overproduction of a substance that prevents cells from maturing and causes them to grow out of control.

By inhibiting the mutated IDH1 enzyme, this medication helps to decrease the number of abnormal cells and encourages the development of healthy, functional cells. This targeted approach focuses on the specific molecular changes that drive the growth of the cancer.

Question 2

What is Tibsovo used for?

Accepted Answer

Tibsovo is used to treat IDH1 mutation-positive acute myeloid leukemia and IDH1 mutation-positive cholangiocarcinoma .

Question 3

How does Tibsovo work?

Accepted Answer

Targeting IDH1 Mutations

Tibsovo is a type of targeted therapy known as an IDH1 inhibitor. It works by identifying and blocking a specific mutated version of an enzyme called isocitrate dehydrogenase-1 (IDH1). This mutation is often present in certain blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as bile duct cancers.

Restoring Normal Cell Development

In cancers with this mutation, the IDH1 enzyme produces an abnormal chemical called 2-hydroxyglutarate (2-HG). When 2-HG levels are too high, it prevents young cells from maturing into healthy, functional cells. Instead, these cells remain immature and multiply rapidly, leading to the growth of the cancer.

Tibsovo works through the following process:

Enzyme Inhibition: The medication binds to the mutated IDH1 enzyme to prevent it from producing 2-HG.

Lowering Metabolite Levels: By stopping the production of 2-HG, the medication reduces the concentration of this abnormal chemical in the body.

Cell Differentiation: Once the levels of 2-HG are lowered, the immature cancer cells are often able to mature (differentiate) into normal, healthy cells that can function properly.

By encouraging these cells to mature rather than multiply uncontrollably, Tibsovo helps to slow or stop the spread of the disease.

Question 4

What are the active ingredients in Tibsovo?

Accepted Answer

The active ingredient in Tibsovo is ivosidenib .

Question 5

What are the side effects of Tibsovo?

Accepted Answer

Common side effects of Tibsovo may include:

Fatigue

Nausea

Diarrhea

Others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Tibsovo?

Accepted Answer

Tibsovo belongs to the IDH1 inhibitor drug class.

Question 7

What is the dosage of Tibsovo and how do I take it?

Accepted Answer

How to Take Tibsovo

Tibsovo is a tablet taken by mouth. It is usually taken once a day and should be taken at the same time every day to maintain consistent levels of the medication in your body. Swallow the tablets whole; do not crush, chew, or break them.

Food Considerations

You may take Tibsovo with or without food. However, you should avoid taking your dose with a high-fat meal, as this can affect how the medication is absorbed and may increase the risk of side effects.

Missed Doses and Vomiting

If you miss a dose, take it as soon as you remember on the same day. If your next dose is due within a short period, skip the missed dose and continue with your regular schedule. Do not take two doses at once to make up for a missed one.

If you vomit after taking a dose, do not take an additional dose to replace it. Simply wait and take your next dose at the regularly scheduled time.

Question 8

Is Tibsovo safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Tibsovo can cause harm to a fetus. There is limited data on the use of this medication in pregnant humans, but animal studies have shown potential risks to the fetus. Patients should inform their healthcare provider if they are pregnant or plan to become pregnant.

Individuals who can become pregnant should use effective contraception during treatment and for at least one month after the final dose. Tibsovo may reduce the effectiveness of hormonal contraceptives, such as birth control pills, injections, or implants. For this reason, a barrier method (such as condoms) should also be used to prevent pregnancy.

Breastfeeding

It is not known if Tibsovo passes into human breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for at least one month after the last dose.

Question 9

What forms and strengths does Tibsovo come in?

Accepted Answer

Tibsovo is supplied as a film-coated tablet. This medication is intended for oral use and is typically swallowed whole.

Question 10

What is the FDA approval status of Tibsovo?

Accepted Answer

FDA Approval and Indications

Tibsovo was first approved by the U.S. Food and Drug Administration (FDA) in 2018. It is currently approved for use in adults whose cancer has a specific mutation in the isocitrate dehydrogenase-1 (IDH1) gene. Its approved uses include:

Acute Myeloid Leukemia (AML): It is used for newly diagnosed AML in adults who are 75 years or older or who have health conditions that prevent the use of intensive chemotherapy. It is also approved for adults with AML that has returned (relapsed) or did not respond to previous treatments (refractory).

Cholangiocarcinoma: It is approved for adults with bile duct cancer that has spread or cannot be removed by surgery, and who have already received at least one prior treatment.

Myelodysplastic Syndromes (MDS): It is approved for adults with relapsed or refractory MDS.

Boxed Warning

The FDA has required a boxed warning for Tibsovo regarding the risk of differentiation syndrome. This is a serious condition where the drug causes rapid changes in the number and type of blood cells, which can be fatal if not treated. Symptoms may include fever, cough, difficulty breathing, swelling in the arms or legs, and rapid weight gain. Healthcare providers monitor patients closely for these signs, particularly during the first few weeks of treatment.

Regulatory History

Since its initial 2018 approval for relapsed or refractory AML, the FDA has expanded Tibsovo's indications several times. In 2019, it was approved as a single therapy for newly diagnosed AML in older adults. In 2021, the FDA granted approval for its use in bile duct cancer. In 2022, it was approved for use in combination with the drug azacitidine for newly diagnosed AML. In 2023, the FDA expanded its use to include patients with certain types of myelodysplastic syndromes.

Question 11

What should I know about Tibsovo and cost?

Accepted Answer

The actual price a patient pays for Tibsovo can vary significantly. Key factors include:

Insurance Plan: Coverage levels for brand-name oncology drugs vary between private insurance, Medicare, and Medicaid. Patients may be responsible for deductibles, copayments, or coinsurance.

Pharmacy Type: Tibsovo is often distributed through specialty pharmacies. These pharmacies handle complex medications and may have different pricing structures than local retail pharmacies.

Manufacturer Programs: Financial assistance or patient support programs may be available to help reduce out-of-pocket expenses for those who qualify.

It is recommended that patients work with their healthcare team and insurance provider to understand the specific costs associated with their treatment plan.

Tibsovo

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Found an Error?